**Pneumocystis jiroveci** Pneumonia in Patients with Non-Hodgkin’s Lymphoma Receiving Chemotherapy Containing Rituximab

Hung Chang1,4*, Huei-Chung Yeh2, Yung-Cheng Su1, Ming-Hsun Lee3,4
1Division of Hematology-Oncology, 2Department of Gastroenterology and Hepatology, and 3Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, and 4Chang Gung University College of Medicine, Taoyuan Taiwan, R.O.C.

Rituximab enhances treatment efficacy of B-lineage lymphoma by targeting CD20+ B-cells. Such target therapies may compromise the immune system and render patients susceptible to opportunistic infections. We report 2 cases of lymphoma complicated with *Pneumocystis jiroveci* (previously known as *P. carinii*) pneumonia (PCP) while being treated with rituximab-containing chemotherapy regimens. In both cases, PCP developed during the neutropenic period. With timely diagnosis and proper management, both were treated successfully. We searched the literature and found that such opportunistic infection occurred only infrequently in lymphoma patients, and it has not been reported in the large-scale clinical trials of rituximab. Such cases demonstrate the importance of taking PCP into diagnostic consideration in lymphoma patients receiving similar therapies. [J Chin Med Assoc 2008;71(11):579–582]

**Key Words:** febrile neutropenia, lymphoma, opportunistic infection, *Pneumocystis jiroveci*, rituximab

**Introduction**

Rituximab is a monoclonal antibody which enhances the treatment efficacy of B-lineage lymphomas.1,2 It may be associated with compromise of immunity and subsequent opportunistic infections.3,4 *Pneumocystis jiroveci* (previously known as *P. carinii*) pneumonia (PCP) may occur in a wide range of hematologic diseases, notably lymphomas.5-7 In lymphomas, its incidence appears to be related to treatment intensity.8 With the standard regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) with or without rituximab, such an opportunistic infection occurs infrequently. However, PCP can be possibly overlooked, so the true incidence is obscure. The present published guidelines for empirical therapy for febrile neutropenic patients do not include PCP in the early assessment,9,10 which may potentially cause delay in its diagnosis. In this report, we present 2 cases with PCP that occurred after chemotherapy containing rituximab, and discuss the importance of clinical alertness in the neutropenic period.

**Case Reports**

**Case 1**

A 45-year-old female was diagnosed with follicular lymphoma, grade I, in December 2005. The tumor was in stage IVa, with bone marrow involvement. She received chemotherapy with CHOP, consisting of: cyclophosphamide 750 mg/m², day 1; doxorubicin 50 mg/m², day 1; vincristine 2 mg, day 1; and prednisolone 100 mg/day for 5 days. The same regimen was repeated in 3 weeks. Severe neutropenia (white blood cell count [WBC] 1,900/mm³ and absolute neutrophil count 437/mm³) and digital paresthesia occurred following chemotherapy, although there was no overt infection. Doxorubicin was omitted in the 3rd cycle of chemotherapy. Rituximab 375 mg/m² was added to the treatment (R-CHOP). Only 75% of doxorubicin was given in the 4th, 5th and 6th cycles.

On April 19, 2006, after 3 cycles of R-CHOP and a total of 6 cycles of chemotherapy, the patient was admitted with fever. She also complained of cough with scant sputum and mild substernal chest pain. Physical
examination did not show remarkable findings. Laboratory data showed hemoglobin of 12.8 g/dL, platelets of 208,000/mm³, and WBC of 1,300/mm³ with 83% neutrophils, 5% monocytes, 2% eosinophils, 9% lymphocytes and 1% basophils. Biochemistry profile showed normal liver and renal functions. Initial chest film showed only slightly exaggerated lung markings. The patient was treated with ciprofloxacin 300 mg intravenous infusion every 12 hours. The fever persisted, and chest X-ray taken 3 days later revealed some ground glass appearance in the left lung and right lower lung fields (Figure 1A). A high-resolution computed tomography (HRCT) scan the next day disclosed patchy consolidation of bilateral perihilar areas (Figure 1B). The patient did not receive bronchoscopy, and no sputum was available for microbiologic examination.

As PCP was suspected, treatment with trimethoprim-sulfamethoxazole (TMP-SMX) was given at a dose of TMP 5 mg/kg every 6 hours. Fever subsided 2 days after starting TMP-SMX. The treatment was continued for 21 days. Adjunctive steroid was used for 10 days and then tapered off. Follow-up chest film showed a normal result, and the patient was discharged after completing the treatment course for PCP. Another 2 cycles of rituximab plus chemotherapy were given. The dose of doxorubicin was further reduced to 66% in the 7th cycle and omitted in the 8th cycle. No prophylaxis for PCP was given, and she had no further complications.

**Case 2**

A 45-year-old housewife was diagnosed with extranodal marginal zone B-cell lymphoma with diffuse large cell transformation in March 2006. The tumor was in stage IIIEA, with involvement of the stomach and regional lymph nodes. The patient was a hepatitis B carrier, and lamivudine was given as prophylaxis for hepatitis B flare up. She received chemotherapy with CHOP. Neutropenic fever occurred following the first cycle of chemotherapy. Further chemotherapy was given every 3 weeks with dose reduction. Rituximab 375 mg/m² was added to the treatment (R-CHOP) starting from the 3rd cycle of chemotherapy. Due to recurrent severe neutropenia after each cycle of treatment, doxorubicin was omitted in the 6th cycle of chemotherapy on June 26, 2006.

Neutropenic fever developed on July 11 (WBC 2,000/mm³) and she also had mild dry cough. Physical examination showed mild tachypnea (respiratory rate of 28/min) but otherwise unremarkable findings. The initial chest film showed slightly exaggerated lung markings. The patient was treated with ceftriaxone 1 g intravenous injection every 12 hours for 3 days. As the fever persisted, treatment was changed to flomoxef. Chest film was followed-up 6 days later, revealing ground glass appearance in the left lung field (Figure 2A). HRCT scan on the same day revealed slight thickening of the interlobular septa and intralobular interstitium in the left lung with multifocal ground glass opacities (Figure 2B).

Gomori’s methenamine silver nitrate stain of the bronchoalveolar fluid detected the existence of *P. jiroveci* in the lungs. Treatment with TMP-SMX at a dose of TMP 5 mg/kg every 6 hours was instituted, and the fever subsided the following day. Seven days after starting TMP-SMX, WBC decreased to 1,900/mm³.
with 1% myelocytes, 82% neutrophils, 8% monocytes, 1% eosinophils and 8% lymphocytes. Follow-up chest film showed no more infiltrates. TMP-SMX was replaced with clindamycin 600 mg intravenous infusion every 8 hours for suspected TMP-SMX-related neutropenia. The treatment was continued for a total of 21 days. No prophylaxis for PCP was given following complete treatment. Two more cycles of R-CHOP were given without further complications.

**Discussion**

PCP is an opportunistic infection occurring in immunocompromised hosts such as those with acquired immunodeficiency syndrome (AIDS) or recipients of organ transplantations. PCP may occur in a variety of hematologic diseases, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, acute leukemias, chronic myeloid leukemia, multiple myeloma, myelodysplastic syndrome, Hodgkin’s disease and thrombocytopenia. Stem cell transplantation is by far the most immunocompromised state among hematologic diseases. Such patients usually receive TMP-SMX prophylaxis. The incidence of PCP in such a prophylactic setting is low. For patients treated with conventional chemotherapy, non-Hodgkin’s lymphoma is the most common malignancy associated with such opportunistic infections. It has been well demonstrated that chemotherapy used for lymphoma may cause severe and prolonged depression of CD4 cell counts and levels of immunoglobulin. In some intensive treatment modalities, PCP occurs so frequently that routine prophylaxis is recommended.

Compared with infection caused by other pathogens, PCP can be significantly overlooked, especially in the presence of neutropenia. The treatment guidelines for empirical therapy of febrile neutropenia do not include treatment for PCP in the early phase. As PCP patients frequently have hypoxemia, failure to recognize early PCP may result in unfavorable outcomes. Both of our cases developed PCP in the setting of febrile neutropenia. Both received broad-spectrum antibiotics as the initial empirical treatment. With clinical alertness, the diagnosis of PCP was suspected by chest films taken 3 and 6 days after the onset of fever. In both cases, diagnosis was supported by HRCT on the same day that the chest film was taken. Specific treatment of PCP was also initiated on the same day.

Bronchoalveolar lavage cytology was performed in Case 2, confirming the diagnosis by Gomori’s methenamine silver nitrate stain. Our experience demonstrated that PCP should be listed in the differential diagnoses of febrile neutropenia in patients with hematologic diseases, especially lymphoma. Early evaluation for PCP should also be considered in the treatment guidelines for such patients. As for treatment, although TMP-SMX is effective in the majority of cases, it may be intolerable due to gastrointestinal upset, allergic reactions or bone marrow suppression. In such conditions, clindamycin/ primaquine is an alternative therapy, as illustrated by the use of clindamycin in Case 2 ( primaquine was not available in our ward at that time).

Rituximab is a chimeric monoclonal antibody directed against CD20. Used in conjunction with conventional chemotherapy, it increases the treatment efficacy of B-lineage lymphomas. On the other hand, it may cause immunosuppression, rendering patients...
prone to infection by microorganisms such as fungi and cytomegalovirus.\(^3,4\)

In the clinical trials done by Coiffier et al, 197 patients aged between 60 and 80 years received treatment with CHOP, while 202 patients received R-CHOP. In the R-CHOP arm, there were 12 cases with grade 3 to 4 infection and 8 cases of lung toxicity, but no case with frank PCP was reported.\(^1\) Another controlled randomized trial enrolled 824 patients between 18 and 60 years of age. No case with frank PCP was reported in either arm.\(^1\) Whether or not PCP prophylaxis was given to the enrolled cases was not described, but it can be shown that PCP is rare during such treatment courses. On the other hand, in more intensive treatment, patients were given R-CHOP at a 2-week interval; 7 interstitial pneumonitis and 3 documented PCP cases occurred among 50 patients.\(^8\) It was also demonstrated that occurrence of PCP was correlated with hypogammaglobulinemia.\(^8\) It reflected that immunosuppression may be more profound during more intensive treatment and the likelihood for developing opportunistic infection higher. Since rituximab suppresses CD20\(^+\) lymphocytes and leads to hypogammaglobulinemia, it will add to the potential risk of PCP or other opportunistic infections.

In clinical practice, PCP can be easily overlooked in patients treated with conventional regimens. In the absence of routine prophylaxis with TMP-SMX, the true incidence is not shown in any large-scale studies. Our cases received chemotherapy containing rituximab at the conventional 3- to 4-week intervals. PCP was not reported in previous clinical trials that used treatment of similar intensity. It is hoped that this report will draw attention to this opportunistic infection. As early diagnosis and proper treatment are important, clinicians should be highly alert to such complications. Although the guidelines for febrile neutropenia do not include PCP in the early assessment, PCP should be considered in the early phase of febrile neutropenia in patients with hematologic malignancies. Prophylaxis with TMP-SMX may be warranted if more studies showing the occurrence of PCP are available in the future.

References